fbpx
Wikipedia

CSL Limited

CSL Limited is an Australian multinational specialty biotechnology company that researches, develops, manufactures, and markets products to treat and prevent serious human medical conditions. CSL's product areas include blood plasma derivatives, vaccines, antivenom, and cell culture reagents used in various medical and genetic research and manufacturing applications.[3] The company was established in 1916 as Commonwealth Serum Laboratories and was wholly owned by the Australian federal government until its privatisation in 1994.

CSL Limited
TypePublic
IndustryBiotechnology
Founded1916 (Federal government department), 1994 (privatised)
HeadquartersParkville, Melbourne, Victoria, Australia (Global),[1]
Key people
Paul McKenzie (CEO)
Productsblood plasma, vaccines, antivenom, other laboratory and medical products
RevenueUS$10.61 billion (2021))[2]
US$1.919 billion (2021)[2]
Number of employees
30,000 person (2021)[2]
Divisions
  • CSL Behring
  • CSL Seqirus
  • CSL Plasma
  • CSL Vifor
Websitewww.csl.com

History Edit

Origin and Penfold directorship Edit

CSL was founded in 1916 as Commonwealth Serum Laboratories, an Australian government body focused on vaccine manufacture.[4] Under the first director, William Penfold,[5] CSL commenced operation in the vacant Walter and Eliza Hall Institute building at the Royal Melbourne Hospital in 1918 before moving to its purpose-built Parkville premises in the following year.

Morgan directorship Edit

After ongoing disputes with the Department of Health and its director-general John Cumpston, Penfold resigned in 1927 and was replaced by Frederic Morgan.[6] Soon after Morgan's appointment, CSL was drawn into a serious public health disaster when a batch of its diphtheria toxin-antitoxin was implicated in the deaths of twelve children in what became known as the Bundaberg tragedy of 1928. Although CSL's manufacturing processes were absolved, its labelling procedures were seen to be in error, leading to an enduring focus on the highest standards across the facility's production.[7]

Antivenene research and production Edit

In 1928, CSL also became involved in antivenene (antivenom) manufacture in conjunction with the snake venom research undertaken by Charles Kellaway at the Hall Institute.[8] This led to the successful clinical testing of antivenene against tiger snake Notechis scutatus bite in 1930 and its commercial release in 1931.

In 1934, the research on snake venoms was transferred from the Hall Institute to CSL under the direction of former snake showman and herpetologist Tom "Pambo" Eades. This represented the initiation of research at the laboratories – an outcome its directors had been seeking for over a decade. The relationship with the Hall Institute continued until World War II, particularly via joint projects on viral diseases including polio and influenza coordinated by Frank Macfarlane Burnet and Esmond "Bill" Keogh. Keogh played an important role in the establishment of penicillin production at CSL in 1944 – a critical wartime achievement.[9]

Plasma fractionation and Wiener directorship Edit

In 1952, operation commenced plasma fractionation.[10] Thereafter the range of antivenoms increased, including those against other snake species such as death adder (Acanthophis antarcticus) and the taipan (Oxyuranus scutellatus), plus spiders including the redback (Latrodectus hasselti) and – after much difficulty – the Sydney funnel-web (Atrax robustus). Much of this work, including the introduction in 1962 of a polyvalent antivenom against all of the major terrestrial Australian snakes, occurred under the direction of Saul Wiener, while from 1966 until the mid-1990s, venom research was coordinated by the eccentric but dedicated Struan Sutherland, who in 1979 released new guidelines for snakebite first aid,[11] and a new test for snakebites that would identify which snake had envenomated the victim.[12]

Other major achievements of CSL include:[13]

Privatisation Edit

In 1994, the Commonwealth facility was privatised by the Keating government as CSL Ltd. and was publicly listed and traded on the Australian Securities Exchange. The company completed an initial public offering in June 1994 at A$2.30 per share (76.7c adjusted for split). CSL stock is part of the S&P/ASX 20 Index.[15]

Acquisition of ZLB Bioplasma AG and Aventis Behring Edit

In 2000, CSL doubled its size through the purchase of a Swiss plasma company, the Bern-based ZLB Bioplasma AG.[16] In 2004, during a period of plasma oversupply, the company expanded again with the purchase of the German medical company Aventis Behring.[17] The company was the second Australian public company to have reached a share price of over $100 per share.[18]

Acquisition and merging of Novartis Edit

In October 2014, Novartis announced its intention to sell its influenza vaccine business, including its development pipeline, to CSL for $275 million. CSL merged it into its BioCSL operation.[19]

In November 2015, BioCSL rebranded the combined business with Novartis Influenza Vaccines as Seqirus [Sek-eer-us], creating the world's second-largest influenza vaccine company.[20]

In August 2017, the business announced it would acquire Calimmune and its stem cell therapy platform.[21]

Completed in 2018, Seqirus's Holly Spring, NC, the plant was funded with $59 million from the U.S. government.[22]

in June 2020, CSL announced it would exercise its right to acquire Vitaeris.[23]

In December 2021, the business announced it would acquire Swiss drugmaker, Vifor Pharma AG, for $11.7 billion.[24]

In August 2022, CSL rebranded all of its divisions to start with the CSL name. Therefore, the divisions became CSL Behring, CSL Plasma, CSL Seqirus and CSL Vifor.

Acquisition history Edit

CSL Limited acquisitions
  • CSL Limited (Founded 1916 as Commonwealth Serum Laboratories)
    • ZLB Behring
      • ZLB Bioplasma AG (Acq 2000)
      • Aventis Behring (Acq 2004)
      • Vifor Pharma (Acq 2021)
    • Seqirus (Merged 2014)
      • BioCSL
      • Novartis Influenza Vaccines div.
    • Calimmune (Acq 2017)
    • Vitaeris (Acq 2020)
 
CSL's global headquarters building in Parkville, Victoria

Locations Edit

The company's headquarters remain in Parkville, Victoria, an inner suburb of Melbourne, and has offices and laboratory space in Sydney.

CSL Behring is headquartered in King of Prussia, USA and it has manufacturing operations and R&D laboratories in Broadmeadows, Victoria, the Swiss city of Bern, in Marburg in Germany, and Kankakee, USA.

Seqirus has its headquarters in Maidenhead and has production facilities in Holly Springs, US, Liverpool, UK, and Parkville, Victoria

Vaccines Edit

A/H1N1 2009 pandemic Edit

CSL's vaccine for swine flu, the world's first, was approved in September 2009 for use by people over age 10.[25] The federal government ordered 21 million doses of vaccine for Australians.[26] CSL also provided vaccines for customers in Singapore and the US.

On 28 September 2010, the Australian Therapeutic Goods Administration conducted an analysis of febrile convulsions following immunisation in children following monovalent pandemic H1N1 vaccine (Panvax/Panvax Junior, CSL).[27]

A paper published in the Medical Journal of Australia provides a possible reason for CSL's 2010 flu vaccine causing febrile convulsions in children. The authors hypothesise that suboptimal use of the detergent called deoxycholate – used in the manufacturing process by CSL (one of the few vaccine manufacturers that use it) – to split the flu virus from its membrane may be at fault.[28]

COVID-19 pandemic Edit

On 7 September 2020, CSL signed agreements with the Australian government to supply the University of Queensland vaccine (V451) and to manufacture (with AstraZeneca) the Oxford University vaccine (AZD1222), which would yield nearly 85 million doses for Australians. The agreement was contingent on the future success of clinical trials of these vaccines. Most of the manufacture would occur in Melbourne, Australia.[29][30]

On 11 December 2020, after a high percentage of the University of Queensland vaccine trial participants returned "false positive" results for HIV, it was decided that vaccine development will not proceed to Phase 2/3 trials.[31]

On 23 March 2021, the Therapeutic Goods Administration provisionally approved the first batches, numbering 832,000 doses, of the Oxford–AstraZeneca COVID-19 vaccine manufactured by CSL in its plant in Broadmeadows, Victoria. The Australian Government has contracted CSL to produce 50 million doses of the vaccine.[32]

Divisions Edit

CSL Limited's products can be separated by company division. Some of the key products produced by each division, have included:

Seqirus (bioCSL) Edit

Vaccines:[33]

  • Afluria (influenza vaccine) -- Argentina, Peru, South Africa, Spain, US[33]
    • Enzira—in various different markets[33]
    • Fluvax—in various different markets[33]
    • Nilgrip—in various different markets[33]
  • Afluria Quadrivalent (influenza vaccine) -- Australia, Canada, New Zealand, US[33]
    • Afluria Quad—in various different markets[33]
    • Afluria Tetra—in various different markets[33]
  • Agrippal (influenza vaccine) -- Argentina, Austria, Brazil, Canada, Chile, Colombia, Germany, Italy, Mexico, Spain, Thailand[33]
    • Agriflu—in various different markets[33]
    • Begripal—in various different markets[33]
    • Chiroflu—in various different markets[33]
    • Fluazur—in various different markets[33]
    • Sandovac—in various different markets[33]
  • Audenz (influenza A (H5N1) vaccine) -- US[33]
  • Fluad (influenza vaccine) -- Argentina, Austria, Australia, Brazil, Canada, Denmark, Germany, Italy, Spain, Switzerland, UK, US[33]
    • Chiromas—Spain[33]
  • Fluad Pediatric (influenza vaccine) -- Canada[33]
  • Flucelvax Quadrivalent (influenza vaccine) -- Germany, Italy, Spain, UK, US[33]
  • Q-VAX (Coxiella burnetii vaccine) -- Australia[34]
  • Rapivab (peramivir) -- Australia, US[33]

Antivenoms: (Australia)[34]

CSL Behring (Australia) Edit

[35]

CSL Behring Edit

Immunology:[36]

Coagulation/Bleeding Disorders:

Pulmonary:

  • Zemaira, Respreeza freeze-dried Human Alpha1-proteinase inhibitor (A1-PI)

Critical Care:

  • AlbuRx, Alburex, Albumeon, Human Albumin Behring, Albuminar 25, human albumin solution (5%, 20% or 25% human albumin solutions)
  • Berinert P, freeze-dried human C1-esterase inhibitor (C1-INH) concentrate
  • Beriplex P/N, freeze-dried human prothrombin complex concentrate
  • Haemocomplettan P, RiaSTAP, freeze-dried human fibrinogen (factor I) concentrate
  • Kybernin P, freeze-dried human antithrombin III concentrate
  • Streptase, freeze-dried streptokinase

Wound Healing:

Product availability varies from country to country, depending on registration status.

Honours Edit

In 2011, the company received the Minister's Award for Outstanding Equal Employment Opportunities Initiative for their Thinking Kids Children's Centre.[37]

See also Edit

References Edit

  1. ^ "Annual Report 2019" (PDF). CSL Limited. 2019.
  2. ^ a b c "CSL Annual Report 2021/22". CSL Limited. April 2022. Retrieved 29 March 2023.
  3. ^ "CSL LTD (CSL:ASX): Stock Quote & Company Profile". Bloomberg Businessweek. Archived from the original on 18 January 2013. Retrieved 13 August 2012.
  4. ^ "Trove". trove.nla.gov.au. Retrieved 22 September 2020.
  5. ^ Robin, A. De Q. Penfold, William James (1875–1941). Canberra: National Centre of Biography, Australian National University.
  6. ^ Egan, Bryan, "Morgan, Frederick Grantley (1891–1969)", Australian Dictionary of Biography, Canberra: National Centre of Biography, Australian National University, retrieved 22 September 2020
  7. ^ "BUNDABERG TRAGEDY, Daily Examiner". 14 June 1928. p. 3 – via Trove.
  8. ^ Hobbins, Peter G.; Winkel, Kenneth D. (3 December 2007). "The forgotten successes and sacrifices of Charles Kellaway, director of the Walter and Eliza Hall Institute, 1923–1944". The Medical Journal of Australia. 187 (11): 645–648. doi:10.5694/j.1326-5377.2007.tb01457.x. PMID 18072902. S2CID 23444263.
  9. ^ Gardiner, Lyndsay; Serle, Geoffrey (2000). "Keogh, Esmond Venner (Bill) (1895–1970)". Australian Dictionary of Biography. National Centre of Biography, Australian National University. 15.
  10. ^ Flood, Phillip; Wills, Peter; Lawler, Peter; Ryan, Graeme; Rickard, Kevin A. (2006). Review of Australia's Plasma Fractionation Arrangements (PDF). ISBN 1-74186-121-7.
  11. ^ "SAFER FIRST AID, Papua New Guinea Post-Courier". 18 April 1979. p. 11 – via Trove.
  12. ^ "New test for snake bites, The Canberra Times". 30 October 1979. p. 14 – via Trove.
  13. ^ Tasker, Sarah-Jane (23 April 2016). "Blood, sweat and tears of the CSL century". The Australian.
  14. ^ "A global solution to reducing cervical cancer" (PDF). Uniquest commercialisation stories. The University of Queensland. Retrieved 29 April 2016.
  15. ^ "CSL Limited". Australian Securities Exchange. Retrieved 7 February 2020.
  16. ^ Dow Jones Newswires (9 December 2003). "Australia's CSL Agrees to Acquire Aventis Unit for up to $925 Million". The Wall Street Journal. Retrieved 22 February 2021. … this deal eclipses the A$1 billion (US$740.2 million) CSL spent in 2000 to buy ZLB Bioplasma from the Swiss Red Cross.
  17. ^ "Aventis disposes of Behring unit with $925M sale to Australia's CSL –". thepharmaletter.com. The Pharma Letter. 15 December 2003. from the original on 23 September 2021. Retrieved 22 February 2021. … Aventis says that it has agreed to sell its Aventis Behring blood products business to Australia's CSL …
  18. ^ "CSL bursts through the $100 barrier". Quest Asset Partners. 4 August 2015. from the original on 28 February 2016. Retrieved 22 February 2021.
  19. ^ Phillipidis, Alex (27 October 2014). "Novartis Selling Flu Vaccine Business to CSL for $275M". Genetic Engineering & Biotechnology News. Retrieved 22 May 2020.
  20. ^ Sequirus Commonwealth Serum Laboratories
  21. ^ "CSL Behring Acquires Biotech Company Calimmune and its Proprietary Stem Cell Gene Therapy Platform" (Press release). CSL. 6 August 2017. Retrieved 15 December 2021.
  22. ^ Willman, David (15 March 2020). "Federal vaccine development sites ill-suited to counter covid-19 epidemic". The Washington Post. Retrieved 15 March 2020.
  23. ^ "CSL to Acquire Biotech Company Vitaeris" (Press release). CSL. 6 September 2020. Retrieved 15 December 2021.
  24. ^ Nainan, Nikhil; Koltrowitz, Silke; Murdoch, Scott (14 December 2021). "Australia's CSL to buy Swiss drugmaker Vifor for $11.7 bln". Reuters. Retrieved 15 December 2021.
  25. ^ "Panvax H1N1 Approval For Registration For Use in Australia by Therapeutic Goods Administration". Melbourne, Australia: CSL Limited. 18 September 2009. from the original on 25 September 2009. Retrieved 26 September 2009. CSL Biotherapies, a subsidiary of CSL Limited, Australia's leading biopharmaceutical company, can today confirm that its vaccine against the pandemic (H1N1) 2009 influenza or 'swine flu' has been approved registration for use in people aged 10 years and over.
  26. ^ Tran, Mark (22 July 2009). "First human trials of swine flu vaccine begin in Australia". The Guardian. ISSN 0261-3077. Retrieved 7 September 2020.
  27. ^ Administration, Australian Government Department of Health Therapeutic Goods (28 September 2010). "Analysis of febrile convulsions following immunisation in children following monovalent pandemic H1N1 vaccine (Panvax/Panvax Junior, CSL)". Therapeutic Goods Administration (TGA). Retrieved 25 July 2022.
  28. ^ Kelly, Heath A; Skowronski, Danuta M; De Serres, Gaston; Effler, Paul V (19 September 2011). "Adverse events associated with 2010 CSL and other inactivated influenza vaccines". The Medical Journal of Australia. 195 (6): 318–320. doi:10.5694/mja11.10941. PMID 21929484. S2CID 9389146.
  29. ^ "CSL to manufacture and supply University of Queensland and Oxford University vaccine candidates for Australia". csl.com. 7 September 2020. Retrieved 7 September 2020.
  30. ^ "Australia secures onshore manufacturing agreements for two COVID-19 vaccines | Prime Minister of Australia". pm.gov.au. 7 September 2020. Retrieved 7 September 2020.
  31. ^ "Update on The University of Queensland COVID-19 vaccine" (PDF). CSL Limited. (PDF) from the original on 11 December 2020.
  32. ^ "National medical regulator approves 800,000 Australian-made doses of AstraZeneca vaccine". Australian Broadcasting Corporation. 23 March 2021. Retrieved 9 April 2021.
  33. ^ a b c d e f g h i j k l m n o p q r s t "Products". Seqirus. 6 December 2018. Retrieved 5 February 2020.
  34. ^ a b "Products". Seqirus. Australia. Retrieved 9 February 2020.
  35. ^ "Products". cslbehring.com.au. Retrieved 7 February 2020.
  36. ^ CSL Behring, 3 November 2010
  37. ^ "CSL wins equal opportunity award for onsite childcare centre". CSL Newsroom. CSL. Retrieved 25 October 2016.

Sources Edit

  • AH Brogan, Committed to Saving Lives: a History of the Commonwealth Serum Laboratories (Melbourne: Hyland House, 1990).
  • Dando McCredie, The Fight Against Disease and CSL's Seventy Year Contribution (Richmond: Dando McCredie, c.1986).
  • FG Morgan, 'The Commonwealth Serum Laboratories and their work', Collected Proceedings of the Society of Chemical Industry of Victoria, XXXV (1935), 1015–31.
  • WJ Penfold, 'The Commonwealth Serum Laboratories', Medical Journal of Australia, 1 (14 April 1923), 396–400.
  • Struan K Sutherland, A Venomous Life: the Autobiography of Professor Struan Sutherland (Melbourne: Hyland House, 1998).

limited, this, article, multiple, issues, please, help, improve, discuss, these, issues, talk, page, learn, when, remove, these, template, messages, this, article, rely, excessively, sources, closely, associated, with, subject, potentially, preventing, article. This article has multiple issues Please help improve it or discuss these issues on the talk page Learn how and when to remove these template messages This article may rely excessively on sources too closely associated with the subject potentially preventing the article from being verifiable and neutral Please help improve it by replacing them with more appropriate citations to reliable independent third party sources February 2016 Learn how and when to remove this template message This article needs to be updated Please help update this article to reflect recent events or newly available information November 2020 Learn how and when to remove this template message CSL Limited is an Australian multinational specialty biotechnology company that researches develops manufactures and markets products to treat and prevent serious human medical conditions CSL s product areas include blood plasma derivatives vaccines antivenom and cell culture reagents used in various medical and genetic research and manufacturing applications 3 The company was established in 1916 as Commonwealth Serum Laboratories and was wholly owned by the Australian federal government until its privatisation in 1994 CSL LimitedTypePublicTraded asASX CSLS amp P ASX 200 componentIndustryBiotechnologyFounded1916 Federal government department 1994 privatised HeadquartersParkville Melbourne Victoria Australia Global 1 Key peoplePaul McKenzie CEO Productsblood plasma vaccines antivenom other laboratory and medical productsRevenueUS 10 61 billion 2021 2 Net incomeUS 1 919 billion 2021 2 Number of employees30 000 person 2021 2 DivisionsCSL BehringCSL SeqirusCSL PlasmaCSL ViforWebsitewww wbr csl wbr com Contents 1 History 1 1 Origin and Penfold directorship 1 2 Morgan directorship 1 3 Antivenene research and production 1 4 Plasma fractionation and Wiener directorship 1 5 Privatisation 1 6 Acquisition of ZLB Bioplasma AG and Aventis Behring 1 7 Acquisition and merging of Novartis 1 8 Acquisition history 2 Locations 3 Vaccines 3 1 A H1N1 2009 pandemic 3 2 COVID 19 pandemic 4 Divisions 4 1 Seqirus bioCSL 4 2 CSL Behring Australia 4 3 CSL Behring 5 Honours 6 See also 7 References 8 SourcesHistory EditOrigin and Penfold directorship Edit CSL was founded in 1916 as Commonwealth Serum Laboratories an Australian government body focused on vaccine manufacture 4 Under the first director William Penfold 5 CSL commenced operation in the vacant Walter and Eliza Hall Institute building at the Royal Melbourne Hospital in 1918 before moving to its purpose built Parkville premises in the following year Morgan directorship Edit After ongoing disputes with the Department of Health and its director general John Cumpston Penfold resigned in 1927 and was replaced by Frederic Morgan 6 Soon after Morgan s appointment CSL was drawn into a serious public health disaster when a batch of its diphtheria toxin antitoxin was implicated in the deaths of twelve children in what became known as the Bundaberg tragedy of 1928 Although CSL s manufacturing processes were absolved its labelling procedures were seen to be in error leading to an enduring focus on the highest standards across the facility s production 7 Antivenene research and production Edit In 1928 CSL also became involved in antivenene antivenom manufacture in conjunction with the snake venom research undertaken by Charles Kellaway at the Hall Institute 8 This led to the successful clinical testing of antivenene against tiger snake Notechis scutatus bite in 1930 and its commercial release in 1931 In 1934 the research on snake venoms was transferred from the Hall Institute to CSL under the direction of former snake showman and herpetologist Tom Pambo Eades This represented the initiation of research at the laboratories an outcome its directors had been seeking for over a decade The relationship with the Hall Institute continued until World War II particularly via joint projects on viral diseases including polio and influenza coordinated by Frank Macfarlane Burnet and Esmond Bill Keogh Keogh played an important role in the establishment of penicillin production at CSL in 1944 a critical wartime achievement 9 Plasma fractionation and Wiener directorship Edit In 1952 operation commenced plasma fractionation 10 Thereafter the range of antivenoms increased including those against other snake species such as death adder Acanthophis antarcticus and the taipan Oxyuranus scutellatus plus spiders including the redback Latrodectus hasselti and after much difficulty the Sydney funnel web Atrax robustus Much of this work including the introduction in 1962 of a polyvalent antivenom against all of the major terrestrial Australian snakes occurred under the direction of Saul Wiener while from 1966 until the mid 1990s venom research was coordinated by the eccentric but dedicated Struan Sutherland who in 1979 released new guidelines for snakebite first aid 11 and a new test for snakebites that would identify which snake had envenomated the victim 12 Other major achievements of CSL include 13 early production of insulin for treatment of Australian diabetics 1923 development of a tetanus vaccine 1938 development of a combined vaccine for diphtheria tetanus and whooping cough 1953 rapid adoption and production of a polio vaccine 1956 development of a multi purpose animal vaccine covering pulpy kidney enterotoxemia tetanus black disease malignant oedema and blackleg 1961 production of Rhesus D immunoglobulin to prevent haemolytic disease in newborns due to Rh factor incompatibility 1966 67 pioneering heat treatment to protect blood and plasma products from infection with HIV 1983 collaboration on development of the world s first human papillomavirus vaccine Gardasil building on the pioneering work by Professor Ian Frazer 1994 2005 14 Privatisation Edit In 1994 the Commonwealth facility was privatised by the Keating government as CSL Ltd and was publicly listed and traded on the Australian Securities Exchange The company completed an initial public offering in June 1994 at A 2 30 per share 76 7c adjusted for split CSL stock is part of the S amp P ASX 20 Index 15 Acquisition of ZLB Bioplasma AG and Aventis Behring Edit In 2000 CSL doubled its size through the purchase of a Swiss plasma company the Bern based ZLB Bioplasma AG 16 In 2004 during a period of plasma oversupply the company expanded again with the purchase of the German medical company Aventis Behring 17 The company was the second Australian public company to have reached a share price of over 100 per share 18 Acquisition and merging of Novartis Edit In October 2014 Novartis announced its intention to sell its influenza vaccine business including its development pipeline to CSL for 275 million CSL merged it into its BioCSL operation 19 In November 2015 BioCSL rebranded the combined business with Novartis Influenza Vaccines as Seqirus Sek eer us creating the world s second largest influenza vaccine company 20 In August 2017 the business announced it would acquire Calimmune and its stem cell therapy platform 21 Completed in 2018 Seqirus s Holly Spring NC the plant was funded with 59 million from the U S government 22 in June 2020 CSL announced it would exercise its right to acquire Vitaeris 23 In December 2021 the business announced it would acquire Swiss drugmaker Vifor Pharma AG for 11 7 billion 24 In August 2022 CSL rebranded all of its divisions to start with the CSL name Therefore the divisions became CSL Behring CSL Plasma CSL Seqirus and CSL Vifor Acquisition history Edit CSL Limited acquisitionsCSL Limited Founded 1916 as Commonwealth Serum Laboratories ZLB Behring ZLB Bioplasma AG Acq 2000 Aventis Behring Acq 2004 Vifor Pharma Acq 2021 Seqirus Merged 2014 BioCSL Novartis Influenza Vaccines div Calimmune Acq 2017 Vitaeris Acq 2020 nbsp CSL s global headquarters building in Parkville VictoriaLocations EditThe company s headquarters remain in Parkville Victoria an inner suburb of Melbourne and has offices and laboratory space in Sydney CSL Behring is headquartered in King of Prussia USA and it has manufacturing operations and R amp D laboratories in Broadmeadows Victoria the Swiss city of Bern in Marburg in Germany and Kankakee USA Seqirus has its headquarters in Maidenhead and has production facilities in Holly Springs US Liverpool UK and Parkville VictoriaVaccines EditA H1N1 2009 pandemic Edit See also 2009 swine flu pandemic in Australia CSL s vaccine for swine flu the world s first was approved in September 2009 for use by people over age 10 25 The federal government ordered 21 million doses of vaccine for Australians 26 CSL also provided vaccines for customers in Singapore and the US On 28 September 2010 the Australian Therapeutic Goods Administration conducted an analysis of febrile convulsions following immunisation in children following monovalent pandemic H1N1 vaccine Panvax Panvax Junior CSL 27 A paper published in the Medical Journal of Australia provides a possible reason for CSL s 2010 flu vaccine causing febrile convulsions in children The authors hypothesise that suboptimal use of the detergent called deoxycholate used in the manufacturing process by CSL one of the few vaccine manufacturers that use it to split the flu virus from its membrane may be at fault 28 COVID 19 pandemic Edit See also COVID 19 pandemic in Australia On 7 September 2020 CSL signed agreements with the Australian government to supply the University of Queensland vaccine V451 and to manufacture with AstraZeneca the Oxford University vaccine AZD1222 which would yield nearly 85 million doses for Australians The agreement was contingent on the future success of clinical trials of these vaccines Most of the manufacture would occur in Melbourne Australia 29 30 On 11 December 2020 after a high percentage of the University of Queensland vaccine trial participants returned false positive results for HIV it was decided that vaccine development will not proceed to Phase 2 3 trials 31 On 23 March 2021 the Therapeutic Goods Administration provisionally approved the first batches numbering 832 000 doses of the Oxford AstraZeneca COVID 19 vaccine manufactured by CSL in its plant in Broadmeadows Victoria The Australian Government has contracted CSL to produce 50 million doses of the vaccine 32 Divisions EditCSL Limited s products can be separated by company division Some of the key products produced by each division have included Seqirus bioCSL Edit Vaccines 33 Afluria influenza vaccine Argentina Peru South Africa Spain US 33 Enzira in various different markets 33 Fluvax in various different markets 33 Nilgrip in various different markets 33 Afluria Quadrivalent influenza vaccine Australia Canada New Zealand US 33 Afluria Quad in various different markets 33 Afluria Tetra in various different markets 33 Agrippal influenza vaccine Argentina Austria Brazil Canada Chile Colombia Germany Italy Mexico Spain Thailand 33 Agriflu in various different markets 33 Begripal in various different markets 33 Chiroflu in various different markets 33 Fluazur in various different markets 33 Sandovac in various different markets 33 Audenz influenza A H5N1 vaccine US 33 Fluad influenza vaccine Argentina Austria Australia Brazil Canada Denmark Germany Italy Spain Switzerland UK US 33 Chiromas Spain 33 Fluad Pediatric influenza vaccine Canada 33 Flucelvax Quadrivalent influenza vaccine Germany Italy Spain UK US 33 Q VAX Coxiella burnetii vaccine Australia 34 Rapivab peramivir Australia US 33 Antivenoms Australia 34 Black snake Box jellyfish Brown snake Death adder Funnel web spider Polyvalent snake antivenom Redback spider Sea snake Stonefish Taipan Tiger snake Snake Venom Detection KitCSL Behring Australia Edit Albumex serum albumin Biostate Factor VIII Carimune which is immunoglobulin for intravenous administration IGIV CMV Immunoglobulin VF cytomegalovirus immunoglobulin Helixate which is recombinant Antihemophilic Factor a blood clotting factor for the treatment of haemophilia Hepatitis B immunoglobulin human immunoglobulin Intragam P Normal Rh D Immunoglobulin VF Sandoglobulin MonoFIX VF Factor IX Prothrombinex HT prothrombin complex Rhophylac Rh D immunoglobulin G Tetanus Immunoglobulin VF Thrombotrol VF antithrombin III Vivaglobin sub cutaneous human immune globulin indicated for the treatment of primary immunodeficiency This product gained FDA approval in January 2006 Von Willebrand factor Zoster Immunoglobulin VF varicella zoster immunoglobulin 35 CSL Behring Edit Immunology 36 Beriglobin P human hepatitis A immunoglobulin liquid 16 solution for intramuscular injection Berirab P human rabies immunoglobulin liquid 16 solution for intramuscular injection Carimune NF Sandoglobulin Sanglopor human normal immunoglobulin freeze dried formulations for intravenous administration Cytogam human cytomegalovirus immunoglobulin Liquid immunoglobulin containing a standardized amount of antibody to cytomegalovirus Hepatitis B Immunoglobulin P Behring human hepatitis B immunoglobulin liquid 16 solution for intramuscular injection Hizentra Human normal immunoglobulin Liquid 20 immunoglobulin solution ready to use for subcutaneous administration Privigen human polyvalent immunoglobulin liquid 10 solution for intravenous injection Rhesogamma P human anti D immunoglobulin Prefilled syringes of highly purified anti Rhesus factor D IgG for intravenous administration and intramuscular injection Rhophylac human anti D immunoglobulin Prefilled syringes of highly purified anti Rhesus factor D IgG for intravenous administration and intramuscular injection Sandoglobulin NF Liquid Redimune Redimune NF Liquid human normal immunoglobulin liquid 12 solution for intravenous administration Tetagam P human tetanus immunoglobulin liquid 16 solution for intramuscular injection Varicellon P human varicella immunoglobulin liquid 16 solution for intramuscular injection Vivaglobin human normal immunoglobulin liquid 16 solution for subcutaneous administrationCoagulation Bleeding Disorders Beriate freeze dried human coagulation factor VIII concentrate Berinin P freeze dried human coagulation factor IX concentrate Factor X P Behring a freeze dried human coagulation factor IX and factor X concentrate Fibrogammin P Cluvot and Corifact freeze dried human coagulation factor XIII concentrate Helixate FS and Helixate NexGen freeze dried recombinant coagulation factor VIII Humate P and Haemate P freeze dried human coagulation factor VIII C and von Willebrand factor concentrate Monoclate P a freeze dried monoclonal antibody purified human coagulation factor VIII concentrate Mononine a freeze dried human coagulation factor IX that has been purified using monoclonal antibodies Stimate a synthetic desmopressin acetate nasal spray Octostim a synthetic desmopressin acetate nasal sprayPulmonary Zemaira Respreeza freeze dried Human Alpha1 proteinase inhibitor A1 PI Critical Care AlbuRx Alburex Albumeon Human Albumin Behring Albuminar 25 human albumin solution 5 20 or 25 human albumin solutions Berinert P freeze dried human C1 esterase inhibitor C1 INH concentrate Beriplex P N freeze dried human prothrombin complex concentrate Haemocomplettan P RiaSTAP freeze dried human fibrinogen factor I concentrate Kybernin P freeze dried human antithrombin III concentrate Streptase freeze dried streptokinaseWound Healing Beriplast P Combi Set fibrin sealant kit freeze dried fibrin sealant for topical application Fibrogammin P freeze dried human coagulation factor XIII concentrate TachoComb fibrin sealant fleece type fleece type collagen preparations coated with fibrin glue componentsProduct availability varies from country to country depending on registration status Honours EditIn 2011 the company received the Minister s Award for Outstanding Equal Employment Opportunities Initiative for their Thinking Kids Children s Centre 37 See also EditAustralian Red Cross Blood ServiceReferences Edit Annual Report 2019 PDF CSL Limited 2019 a b c CSL Annual Report 2021 22 CSL Limited April 2022 Retrieved 29 March 2023 CSL LTD CSL ASX Stock Quote amp Company Profile Bloomberg Businessweek Archived from the original on 18 January 2013 Retrieved 13 August 2012 Trove trove nla gov au Retrieved 22 September 2020 Robin A De Q Penfold William James 1875 1941 Canberra National Centre of Biography Australian National University Egan Bryan Morgan Frederick Grantley 1891 1969 Australian Dictionary of Biography Canberra National Centre of Biography Australian National University retrieved 22 September 2020 BUNDABERG TRAGEDY Daily Examiner 14 June 1928 p 3 via Trove Hobbins Peter G Winkel Kenneth D 3 December 2007 The forgotten successes and sacrifices of Charles Kellaway director of the Walter and Eliza Hall Institute 1923 1944 The Medical Journal of Australia 187 11 645 648 doi 10 5694 j 1326 5377 2007 tb01457 x PMID 18072902 S2CID 23444263 Gardiner Lyndsay Serle Geoffrey 2000 Keogh Esmond Venner Bill 1895 1970 Australian Dictionary of Biography National Centre of Biography Australian National University 15 Flood Phillip Wills Peter Lawler Peter Ryan Graeme Rickard Kevin A 2006 Review of Australia s Plasma Fractionation Arrangements PDF ISBN 1 74186 121 7 SAFER FIRST AID Papua New Guinea Post Courier 18 April 1979 p 11 via Trove New test for snake bites The Canberra Times 30 October 1979 p 14 via Trove Tasker Sarah Jane 23 April 2016 Blood sweat and tears of the CSL century The Australian A global solution to reducing cervical cancer PDF Uniquest commercialisation stories The University of Queensland Retrieved 29 April 2016 CSL Limited Australian Securities Exchange Retrieved 7 February 2020 Dow Jones Newswires 9 December 2003 Australia s CSL Agrees to Acquire Aventis Unit for up to 925 Million The Wall Street Journal Retrieved 22 February 2021 this deal eclipses the A 1 billion US 740 2 million CSL spent in 2000 to buy ZLB Bioplasma from the Swiss Red Cross Aventis disposes of Behring unit with 925M sale to Australia s CSL thepharmaletter com The Pharma Letter 15 December 2003 Archived from the original on 23 September 2021 Retrieved 22 February 2021 Aventis says that it has agreed to sell its Aventis Behring blood products business to Australia s CSL CSL bursts through the 100 barrier Quest Asset Partners 4 August 2015 Archived from the original on 28 February 2016 Retrieved 22 February 2021 Phillipidis Alex 27 October 2014 Novartis Selling Flu Vaccine Business to CSL for 275M Genetic Engineering amp Biotechnology News Retrieved 22 May 2020 Sequirus Commonwealth Serum Laboratories CSL Behring Acquires Biotech Company Calimmune and its Proprietary Stem Cell Gene Therapy Platform Press release CSL 6 August 2017 Retrieved 15 December 2021 Willman David 15 March 2020 Federal vaccine development sites ill suited to counter covid 19 epidemic The Washington Post Retrieved 15 March 2020 CSL to Acquire Biotech Company Vitaeris Press release CSL 6 September 2020 Retrieved 15 December 2021 Nainan Nikhil Koltrowitz Silke Murdoch Scott 14 December 2021 Australia s CSL to buy Swiss drugmaker Vifor for 11 7 bln Reuters Retrieved 15 December 2021 Panvax H1N1 Approval For Registration For Use in Australia by Therapeutic Goods Administration Melbourne Australia CSL Limited 18 September 2009 Archived from the original on 25 September 2009 Retrieved 26 September 2009 CSL Biotherapies a subsidiary of CSL Limited Australia s leading biopharmaceutical company can today confirm that its vaccine against the pandemic H1N1 2009 influenza or swine flu has been approved registration for use in people aged 10 years and over Tran Mark 22 July 2009 First human trials of swine flu vaccine begin in Australia The Guardian ISSN 0261 3077 Retrieved 7 September 2020 Administration Australian Government Department of Health Therapeutic Goods 28 September 2010 Analysis of febrile convulsions following immunisation in children following monovalent pandemic H1N1 vaccine Panvax Panvax Junior CSL Therapeutic Goods Administration TGA Retrieved 25 July 2022 Kelly Heath A Skowronski Danuta M De Serres Gaston Effler Paul V 19 September 2011 Adverse events associated with 2010 CSL and other inactivated influenza vaccines The Medical Journal of Australia 195 6 318 320 doi 10 5694 mja11 10941 PMID 21929484 S2CID 9389146 CSL to manufacture and supply University of Queensland and Oxford University vaccine candidates for Australia csl com 7 September 2020 Retrieved 7 September 2020 Australia secures onshore manufacturing agreements for two COVID 19 vaccines Prime Minister of Australia pm gov au 7 September 2020 Retrieved 7 September 2020 Update on The University of Queensland COVID 19 vaccine PDF CSL Limited Archived PDF from the original on 11 December 2020 National medical regulator approves 800 000 Australian made doses of AstraZeneca vaccine Australian Broadcasting Corporation 23 March 2021 Retrieved 9 April 2021 a b c d e f g h i j k l m n o p q r s t Products Seqirus 6 December 2018 Retrieved 5 February 2020 a b Products Seqirus Australia Retrieved 9 February 2020 Products cslbehring com au Retrieved 7 February 2020 Global product portfolio CSL Behring 3 November 2010 CSL wins equal opportunity award for onsite childcare centre CSL Newsroom CSL Retrieved 25 October 2016 Sources EditAH Brogan Committed to Saving Lives a History of the Commonwealth Serum Laboratories Melbourne Hyland House 1990 Dando McCredie The Fight Against Disease and CSL s Seventy Year Contribution Richmond Dando McCredie c 1986 FG Morgan The Commonwealth Serum Laboratories and their work Collected Proceedings of the Society of Chemical Industry of Victoria XXXV 1935 1015 31 WJ Penfold The Commonwealth Serum Laboratories Medical Journal of Australia 1 14 April 1923 396 400 Struan K Sutherland A Venomous Life the Autobiography of Professor Struan Sutherland Melbourne Hyland House 1998 Retrieved from https en wikipedia org w index php title CSL Limited amp oldid 1175002720, wikipedia, wiki, book, books, library,

article

, read, download, free, free download, mp3, video, mp4, 3gp, jpg, jpeg, gif, png, picture, music, song, movie, book, game, games.